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Abstract
The aim of this study was to characterize and identify the mode of action of IC31H, a two-component vaccine adjuvant. We
found that IC31H was accumulated in human peripheral blood monocytes, MHC class II positive cells and monocyte-derived
DCs (moDCs) but not in plasmacytoid DCs (pDCs). In the presence of IC31H the differentiation of inflammatory CD1a+
moDCs and the secretion of chemokines, TNF-a and IL-6 cytokines was inhibited but the production of IFNb was increased.
Sustained addition of IC31H to differentiating moDCs interfered with IkBa phosphorylation, while the level of phospho-IRF3
increased. We also showed that both IC31H and its KLK component exhibited a booster effect on type I IFN responses
induced by the specific ligands of TLR3 or TLR7/8, whereas TLR9 ligand induces type I IFN production only in the presence of
IC31H or ODN1. Furthermore, long term incubation of moDCs with IC31H caused significantly higher expression of IRF and
IFN genes than a single 24 hr treatment. The adjuvant activity of IC31H on the IFN response was shown to be exerted
through TLRs residing in the vesicular compartment of moDCs. Based on these results IC31H was identified as a moDC
modulatory adjuvant that sets the balance of the NF-kB and IRF3 mediated signaling pathways to the production of IFNb.
Thus IC31H is emerging as a potent adjuvant to increase immune responses against intracellular pathogens and cancer in
future vaccination strategies.
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Introduction
Protein antigens of subunit vaccines are usually poorly
immunogenic and require vaccine adjuvants to enhance their
immunogenicity [1]. Most adjuvants have been shown to induce
and/or enhance adaptive immune responses; however, the
primary targets of adjuvants are not B- and T-lymphocytes but
various cells types of innate immunity [2].
Based on their complex functional activities they have been
identified as major coordinators of innate and adaptive immunity
[3]. These cells can induce antigen-specific inflammatory T cell
responses or, alternatively, suppress T cell activation or trigger
regulatory T-lymphocyte responses thereby playing a pivotal role
in the maintenance of peripheral tolerance [4]. DCs are generated
from bone marrow precursors and represent a minor and
remarkably heterogeneous population of cells [5]. Phenotypic,
migratory and functional properties of DCs classify these cells to
conventional DCs (cDCs) and plasmacytoid DCs (pDCs) [6]. cDCs
derive from common precursors of monocytes and macrophages
and generate both lymphoid organ resident as well as in-
flammatory subsets, which can be activated by various endogenous
and exogenous stimuli [7,8]. In contrast to activated cDCs that
migrate from peripheral tissues to draining lymph nodes through
lymphatics, pDCs reside in peripheral lymphoid organs and when
activated migrate to inflamed tissues. Monocyte-derived DCs
(moDCs) with inflammatory properties have recently been
validated as functionally competent cDCs, which can be generated
in vivo under inflammatory conditions [9] and in vitro in the
presence of specific cytokines [10]. moDCs continuously sense,
internalize and process protein antigens and present their
degradation products to naive T-lymphocytes with concomitant
co-stimulatory signals that drive T-cell activation and differenti-
ation to effector cells with different functional attributes [11].
Due to the expression of a wide variety of pattern recognition
receptors (PRRs) specific for different phylogenetically conserved
pathogen-associated molecular patterns (PAMPs) cDCs are
primary targets of both microbial and particulate adjuvants [1].
Specific ligands of PRRs, liposomes and microparticles activate
DCs directly, whereas mineral salts and various antigen delivery
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systems exert indirect effects on DCs through the stimulation and
recruitment of other blood [12] or stromal cells [13]. It is also well
established that the combination of multiple stimulatory signals
boost adjuvant effects [14,15] and induces the accumulation of
inflammatory cells at the injection site [16]. However, the
molecular mechanisms mediating these complex effects are still
poorly characterized [12].
IC31H is a two-component adjuvant consisting of the artificial
antimicrobial cationic peptide KLK acting as a vehicle [17] and
the TLR9-stimulatory oligodeoxynucleotide ODN1a [18,19].
Several in vivo studies in murine model systems revealed the Th1
and/or Th17 polarizing effect of IC31H when used as an adjuvant
in combination with mycobacterial antigens [20–22], and the
efficacy of IC31H in anti-mycobacterial vaccination of healthy
volunteers was also shown [23,24]. The IC31H component KLK
was shown to facilitate the uptake and delivery of ODN1a into
TLR9-positive intracellular vesicular compartments of human
moDCs [25,26] and based on these properties IC31H was
implicated to have a profound effect on immune responses
triggered by TLR9-agonists [27]. TLR9-mediated stimulation is
intimately linked to type I interferon production and previous
studies in a mouse model revealed the capability of IC31H to
induce peptide specific cytotoxic T cells (CTL) in a type I
interferon and Stat1 dependent manner, however, the exact
mechanism was not identified [28,29]. Based on these results we
hypothesized that type I interferon production contributed to the
adjuvant potential of IC31H and we sought to analyze the effects of
IC31H in human DCs, where TLR9 expression and TLR9-
mediated type I IFN induction has been associated to pDCs [30],
whereas the role of TLR9 in cDCs has remained controversial
[31].
The major goal of the present study was to understand how
IC31H regulates human pDCs and cDCs by monitoring its uptake
by the different cell types and the effect IC31H exerts on DC
differentiation and on various activation pathways. We found that
IC31H does not modulate pDC functions but it has profound
effects on moDC differentiation and activation. Type I IFN
production was stimulated by IC31H enhancing IRF3 activation,
whereas it inhibited the NF-kB mediated chemokine and pro-
inflammatory cytokine responses. Furthermore IC31H exerts
strong booster effect on the IFNb production of moDCs activated
through vesicular TLRs.
Materials and Methods
Isolation and Culturing of Primary pDCs
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll-Paque (GE Healthcare, Uppsala, Sweden) density gradient
centrifugation of heparinized leukocyte-enriched buffy-coats of
healthy donors drawn at the Regional Blood Center of Hungarian
National Blood Transfusion Service (Debrecen, Hungary) in
accordance with the written approval of the Director of the
National Blood Transfusion Service and the Regional and
Institutional Ethics Committee of the University of Debrecen,
Medical and Health Science Centre (Debrecen, Hungary). Written
informed consent was obtained from the donors prior blood
donation and their data were processed and stored according to
the directives of the European Union. Plasmacytoid DCs were
purified from PBMC by negative selection using the immuno-
magnetic cell separation kit (Miltenyi Biotec, Bergish Gladbach,
Germany) according to the manufacturer’s instruction. After
separation on VarioMACS magnet the purity of BDCA2+
BDCA4+ CD123+ pDCs was .98%, as confirmed by flow
cytometry.
Freshly isolated pDCs were seeded at 1x105 cells/well in 96-well
flat-bottom plates in RPMI 1640 medium (Sigma-Aldrich, St.
Louis, MO, USA) supplemented with 2 mM L-glutamine (Sigma-
Aldrich), 100 U/ml penicillin, 100 ng/ml streptomycin, 10%
heat-inactivated FCS (Invitrogen, Carlsbad, CA, USA) and
50 ng/ml recombinant human IL-3 (Peprotech EC, London, UK).
Stimulation and Flow Cytometric Analysis of pDCs
Freshly isolated primary pDCs were treated with 10 nM KLK
and 0.4 nM ODN1a by using the two components separately or
mixed according to the IC31H mixing protocol provided by
Intercell AG. The treated cells were incubated at 37uC in 5% CO2
humidified atmosphere for 24 h and then the supernatants were
collected and stored at 270uC until cytokine measurements,
whereas the cell were analyzed by flow cytometry. For stimulation
of pDCs in whole blood, peripheral blood samples of healthy
donors were exposed to IC31H and its components for 24 h. After
incubation the blood samples were labeled with fluorescence-
conjugated monoclonal antibodies (mAbs) and were lysed with BD
FACS Lysing Solution (BD Biosciences) to eliminate red blood
cells before flow cytometric analysis. Expression of cell surface
proteins was analyzed by staining the cells with FITC-labeled
mAbs specific for CD40, CD62L (BD Pharmingen, San Diego,
CA, USA), CD80 (BioLegend, Uithoorn, The Netherlands) and
PE-labeled human mAbs recognizing CXCR4, CCR2, CCR7
(R&D System, Minneapolis, MN, USA), CD84 (BD Pharmingen)
and APC-labeled human mAbs against CXCR3, CCR5, CD38
(R&D System) and PE-Cy5-labeled anti-CD83 (BD Pharmingen).
Isotype-matched control antibodies (Abs) were obtained from BD
Pharmingen. In whole blood samples pDCs were identified by
single positive staining with the anti-BDCA-4 mAb conjugated
with APC (Miltenyi Biotec) and was further identified by back
gating to light scatter parameters to get a homogenous population
of pDCs [32]. Fluorescence intensities were measured by
FACSCalibur flow cytometer (BD Biosciences Immunocytometry
Systems, Franklin Lakes, NJ, USA) and data analysis was
performed by the FlowJo software (TreeStar, Ashland, OR,
USA). Uptake of FITC-conjugated KLK and/or Cy5-labeled
ODN1a by pDCs was investigated in PBMC cultures at both 37uC
and 0uC. pDCs were identified in PBMCs by using PE-labeled
human anti-BDCA-2 mAb (Miltenyi Biotec) and light scatter
parameters.
Isolation of Monocytes, Differentiation and Activation of
moDCs and their Characterization by Flow Cytometry
Leukocyte-enriched buffy coats were obtained from healthy
blood donors drawn at the Regional Blood Center of Hungarian
National Blood Transfusion Service (Debrecen, Hungary). PBMCs
were separated by standard density gradient centrifugation with
Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden).
Monocytes were purified from PBMCs by positive selection using
immunomagnetic cell separation with anti-CD14 microbeads
according to the manufacturer’s instruction (Miltenyi Biotec).
After separation on a VarioMACS magnet 96–99% of the cells
were CD14+ monocytes as measured by flow cytometry. Mono-
cytes were cultured in 12-well tissue culture plates at a density of
26106 cells/ml in AIM-V medium (Invitrogen) supplemented with
80 ng/ml GM-CSF (Gentaur Molecular Products, Brussels,
Belgium) and 100 ng/ml IL-4 (Peprotech EC). On day 2 the
same amounts of GM-CSF and IL-4 were added to the cell
cultures.
Phenotyping of resting and activated moDCs was performed by
flow cytometry using anti-CD83 and anti-CD1a mAbs and
isotype-matched control Abs (BD Pharmingen). Fluorescence
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Figure 1. Distribution of fluorescent ODN1a, KLK and IC31H in human peripheral bloodmononuclear cells and in monocyte-derived
dendritic cell subsets. A - Human peripheral blood mononuclear cells (PBMC) were incubated with Cy5-conjugated ODN1a, FITC-conjugated KLK
and IC31H containing both fluorescent components for 1 h either on ice (thin line) or at 37uC (thick line). Fluorescence intensities were measured by
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intensities were measured by FACSCalibur cytometer (BD
Biosciences) and data were analyzed by the FlowJo software (Tree
Star). KLK-FITC and ODN1a-Cy5 uptake was investigated at
37uC and 0uC as control. The cell population of interest was gated
according the forward and side light scatter properties. The
possible cytotoxic effect of KLK, ODN1a and IC31H was
monitored by an Annexin-V/PI kit.
Bacterial lipopolysaccharide (LPS) (Sigma-Aldrich), human
recombinant IFNc (Peprotech EC), high molecular weight
polyinosinic:polycytidylic acid (pI:C), CL075 and CpG2216
(InvivoGen, San Diego, CA, USA) were used at concentrations
indicated in the Figure legends. To prepare cell lysates for Western
blotting DCs were activated for 24h. Cell culture supernatants for
ELISA were collected and cell lysates were prepared for real-time
quantitative polymerase chain reaction (QPCR) after 18–24-h
stimulation. KLK and ODN1a were used as described above.
RNA Isolation, cDNA Synthesis and QPCR
To analyze the relative changes in gene expression QPCR was
performed as described previously [33]. Briefly, total RNA was
isolated by TRIzol reagent (Invitrogen) and 1.5–2 mg of total RNA
were reverse transcribed using SuperScript II RNase H reverse
transcriptase (Invitrogen) and Oligo(dT)15 primers (Promega,
Madison, WI, USA). Gene-specific TaqMan assays (Applied
Biosystems, Foster City, CA) were used to perform QPCR in
a final volume of 25 ml in triplicates using AmpliTaq DNA
polymerase and ABI Prism 7900HT real-time PCR instrument
(Applied Biosystems). Amplification of 36B4 was used as normal-
izing control. Cycle threshold values (Ct) were determined using
the SDS 2.1 software. Constant threshold values were set for each
gene throughout the study. The sequence of the primers and
probes are available upon request.
Chemokine Array
Chemokine gene expression profiling of control and IC31H-
treated moDCs was studied with the Human Chemokines &
Receptors PCR Array assay (SABiosciences, Frederick, MD, USA)
in accordance with the manufacturer’s recommendations. Briefly,
total RNA was isolated from the untreated and treated cells using
RNeasy Mini Kit. After DNase I digestion first strand cDNA
synthesis was performed by using the RT2 First Strand Kit
(SABiosciences) following the manufacturer’s instructions and
including a genomic DNA elimination step and external RNA
controls. For each sample 900 ng of total RNA was reverse
transcribed. Real-time PCR measurement was performed using
the RT2 qPCR Master mix (SABiosciences) according to the
manufacturer’s instructions on the ABI Prism 7000 real-time PCR
platform. For each analysis 25 ml of the experimental cocktail of
the cDNA samples and RT2 qPCR Master mix was distributed
across the PCR array 96 well plates each of which contained 84
wells with a real-time PCR assay for different chemokine genes, 5
wells with assays for different housekeeping genes, a genomic DNA
control, 3 replicate Reverse Transcription controls and 3 replicate
Positive PCR controls. A two-step cycling program was used
consisting of an initial activating step of 10 min at 95uC and
a second step of 40 cycles of denaturation (95uC, 15 s) and
annealing (60uC, 1 min). Finally, each plate underwent a melting
curve program (95uC, 1 min; 65uC, 2 min (optics off); 65uC to
95uC at 2uC/min (optics on). Gene expression levels were
determined as the inverse of the Ct value. Ct values greater than
35 or those not detected were set to 35. After cycling with real-
time PCR the amplification data were analyzed and statistical
significance was calculated by SABiosciences on-line software.
siRNA Experiments
Gene specific siRNA knockdown was performed by SilencerSe-
lect siRNA (Applied Biosystems) transfection on day 3 using
GenePulser Xcell instrument (Bio-Rad, Hercules, CA, USA).
Silencing of RLR genes was performed by RIG-I and MDA5
siRNA mix and Silencer Negative Control non-targeting siRNA
(Applied Biosystems) was used as a negative control. The efficiency
of siRNA treatments was tested before and after DC activation on
days 5 and 6 by Q-PCR and Western blotting.
Western Blotting
Cells were lysed in Laemmli buffer and the protein extracts were
tested by Abs specific for TLR3 (Abcam, Cambridge, UK), MDA5
(Lifespan, Seattle, WA, USA), RIG-I, IkB-a, phospho-IkB-a,
IRF3, phospho-IRF3 (Cell Signaling, Danvers, MA, USA) and b-
actin (Sigma-Aldrich) diluted to 1:1000, the secondary Ab was
used at 1:5000. Anti-rabbit or anti-mouse (pIkB-a) Abs conjugated
to horseradish peroxidase (GE Healthcare) were used as secondary
Abs. The SuperSignal enhanced chemiluminescence system was
used for probing the target proteins (Thermo Scientific, Rockford,
IL, USA). After the membranes had been probed for the target
protein they were stripped and re-probed for b-actin.
flow cytometry in monocytes (upper panel) identified by their light scatter properties, MHC class II+ (middle panel) and MHC class II2 (lower panel)
lymphocyte populations discriminated by PE-conjugated HLA-D-specific Ab. Unstained controls are shown as thick (37uC) or thin (0uC) dashed lines.
Cells stained by KLK-FITC (left column) or ODN1a-Cy5 (middle and right columns) are shown. A typical experiment out of three is documented. B -
Human monocyte-derived DCs were harvested on day 5 of in vitro differentiation and incubated with KLK, ODN1a or IC31H as described in Figure 1A.
The cells were kept either on ice (thin lines) or incubated at 37uC (thick lines). KLK-FITC (left column) and the ODN1a-Cy5 fluorescence intensities
(middle and right columns) were evaluated by flow cytometry. CD1a positive (upper panel) and CD1a negative (lower panel) moDCs were
discriminated by gating the cells based on their staining with a PE-conjugated CD1a-specific antibody. Controls, incubated without KLK-FITC or/and
ODN1a-Cy5 are shown by thick and thin dashed lines (CD1a positive and CD1a negative moDCs, respectively). A typical experiment out of three is
shown.
doi:10.1371/journal.pone.0055264.g001
Table 1. Distribution of IC31H and its components in
peripheral blood mononuclear cells.
DMFI values
Treatment KLK ODN1a IC31H
Fluorescence KLK-FITC ODN1a-Cy5
Temperature 37uC 0uC 37uC 0uC 37uC 0uC
monocytes 2066.55 1615.52 91.71 9.75 9907.81 9907.75
HLA-D+
lymphocytes
80.99 44.49 12.29 1.29 983.19 564.09
HLA-D2
lymphocytes
4.6 12.07 10.2 0.36 50 124.51
doi:10.1371/journal.pone.0055264.t001
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Figure 2. The effect of KLK, ODN1a and IC31H on the differentiation and activation of monocyte-derived dendritic cell subsets. A -
Human moDCs were differentiated for 5 days in the absence (control) or presence of KLK, ODN1a or IC31H, added on days 0 and 2 to the cultures
(Protocol A, Figure S2) together with the differentiating cytokines IL-4 and GM-CSF. The distribution of CD1a2 and CD1a+ cells was monitored by flow
cytometry. Samples stained by CD1a-specific antibody or isotype-matched control antibody (dashed line) are shown. B – Human moDCs were
differentiated as described in Figure 2A and on day 5 they were activated by 100 ng/ml LPS +10 ng/ml IFNc in combination with KLK, ODN1a and
IC31H for 24 h (Protocol B, Figure S2). Activation of DCs was evaluated on day 6 by detection of the cell surface expression of CD83 using flow
cytometry. Data from a typical experiment out of three independent experiments are shown.
doi:10.1371/journal.pone.0055264.g002
Figure 3. The effect of KLK, ODN1 and IC31H on the cytokine production of monocyte-derived dendritic cells. Human moDCs were
differentiated and activated as described in Protocol B (Figure S2) (IDC: non-activated immature dendritic cells; MDC: 100 ng/ml LPS +10 ng/ml IFNc -
activated mature dendritic cells). A – Supernatants of DC cultures were collected on day 6 and the concentration of IL-6, TNF-a and IFNb was
measured by ELISA. Mean6SEM values of 3 independent experiments performed with moDCs obtained from different donors are presented.
Statistically significant changes were calculated as described in the Material and Methods. B – Gene expression profile of chemokine and cytokine
genes in DCs treated as described in Protocol B. Fold increase values of two independent donors are presented as mean6SD of triplicate
measurements. C – Activation of the NF-kB and IRF3 pathways was evaluated in cell lysates by detection of phosphorylation state of IkBa and IRF3
using Western blotting. Data of a representative DC donor out of three are shown.
doi:10.1371/journal.pone.0055264.g003
Effects of IC31 on Endosomal DC Signaling
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e55264
Effects of IC31 on Endosomal DC Signaling
PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e55264
Cytokine Measurements
Culture supernatants of DCs were harvested 24 h after
activation and the concentrations of IL-6, IL-8 and TNF-a were
measured using OptEIA kits (BD Biosciences). The level of
secreted IFNb was measured by Human Interferon beta ELISA
Kits (Cell Sciences, Canton, MA, USA) according to the
manufacturer’s protocol. Absorbance measurements were per-
formed with a Synergy HT reader (Bio-Tek Instruments,
Winooski, VT, USA) at 450 nm. Secreted MIP-1a, MIP-1b and
IFN-a levels were measured with FlowCytomix kits (eBioscience,
Vienna, Austria) by flow cytometry. The data were analysed by the
FlowCytomix Pro 2.2 Software (eBioscience).
Statistics
Data are presented as mean 6 SEM, p values were calculated
using the Student’s t test. p,0.05 was considered as statistically
significant; *p,0.05, **p,0.01, ***p,0.005 and ****p,0.001.
Results
1. Accumulation of IC31H and its Components in Human
Peripheral Blood Mononuclear Cell Populations
Cell type-specificity and cellular compartmentalization of PRRs
have an important impact on the functional activity of vaccine
adjuvants [34]. Thus we first tried to identify the cell types in
human PBMC preferentially involved in the accumulation of
IC31H by using the fluorescence labeled components, KLK and
ODN1a of the adjuvant. We hypothesized that IC31H targets
preferentially phagocytes and professional APCs. Taken the
unique functional attributes of pDCs in type I IFN responses
and the expression of TLR9 in this cell type, we tested the effects
of IC31H on the phenotype and functional activities of pDCs in
whole blood and in primary pDC cultures. We found that
fluorescence intensities of blood cells were increased in the
presence of IC31H and its KLK and ODN1a components in
a temperature independent manner but temperature dependent
active internalization of the labeled components could not be
observed (Figure S1). When pDCs were tested in erythrocyte
depleted peripheral blood IC31H could not induce the expression
of the CD80, CD83, CD84, CD40, CD38 activation markers and
CD62L expression on the surface (Table S1A). In line with the
lack of pDC activation the cells were unable to produce IFNa,
TNF-a, IL-6 and IL-8 cytokines (data not shown) and changes in
the cell surface expression of CCR2, CCR5 and CXCR3 also
could not be detected (Table S1B). However, we found
significantly increased expression of CCR7 and CXCR4 on pDCs
induced by IC31H. To test whether upregulation of these
chemokine receptors was a direct effect of IC31H on pDCs we
performed experiments with isolated pDCs after short term in vitro
cultures, but no effect could be detected (Table S1B). These results
suggested an indirect effect of IC31H on chemokine receptor
expression likely mediated by other blood cell types and/or their
products.
When we compared fluorescence intensities of different cell
fractions of human PBMC we found that monocytes and MHC
class II positive cells, which involve mostly B-lymphocytes, were
stained very strongly by KLK-FITC as compared to MHC class II
negative cells (Figure 1A, left column; Table 1). The highest
fluorescence intensity was measured in monocytes (Figure 1A, left
upper panel; Table 1) whereas staining of the MHC class II
positive cells indicated a heterogeneous cell population with
different fluorescence intensities (Figure 1A, left middle panel).
The left column also indicates the temperature independent
staining of the cells with KLK-FITC in contrast to ODN1a-Cy5,
which exhibits a temperature dependent accumulation in all tested
cell fractions (Figure 1A, middle column; Table 1). However,
staining of ODN1a was shifted to higher fluorescence intensities
when present in IC31H and its temperature dependency could not
be detected anymore (Figure 1A right column; Table 1) indicating
that KLK renders the cells capable to interact with ODN1a in
a temperature independent manner. Although IC31H is accumu-
lated by MHC class II positive cells, which also involve circulating
DCs at low numbers, IC31H is most efficiently accumulated by
monocytes that can give rise to moDCs in both peripheral and
lymphoid tissues. Based on these results we performed our further
experiments with moDCs and tested the effects of IC31H on cell
differentiation, activation and functional activities.
We have previously shown that based on the expression of
CD1a, a protein presenting glyco- and phospholipids of pathogens
such as Mycobacterium tuberculosis, two phenotypically and function-
ally distinct moDC subsets can be separated [33]. It was also
shown that CD1a2 cells are more active in the internalization of
exogenous compounds than their CD1a+ counterparts [33]. To
control whether IC31H uptake was different in these moDC
subsets we compared the fluorescence intensities in CD1a+ and
CD1a2 cells at both 0uC and 37uC (Figure 1B). Marginal
differences could be detected in fluorescence intensities measured
in the CD1a2 and CD1a+ DC subsets suggesting the involvement
of both cell types in interacting with IC31H and its components in
a temperature independent manner.
2. Effect of Prolonged Presence of IC31H on Monocyte-
derived Dendritic Cell Differentiation and Activation
Our previous studies revealed that CD1a2 and CD1a+ DCs are
the result of consecutive differentiation steps and their ratio varies
among individuals [33]. To control the long and short term effects
of IC31H on moDCs we set up various in vitro experimental
systems. In the first system (protocol A) moDCs were differentiated
in the presence of IC31H and its components added to monocytes
on day 0 and to differentiating moDC on day 2 (Figure S2A). In
the second system (protocol B) a similar procedure was performed
but extended by an additional IC31H treatment on day 5 together
with the activation of moDCs by LPS plus IFNc (LPS+IFNc), or
by various TLR ligands to mimic inflammatory conditions (Figure
S2B). In the third system (protocol C) the IC31H adjuvant and its
components were added on day 5 only, combined with the
activation stimuli as in protocol B (Figure S2C).
First monocytes were differentiated in the presence of IC31H,
KLK or ODN1a according to Figure S2A and the ratio of CD1a+
and CD1a2 cells was monitored by flow cytometry. IC31H
dramatically inhibited the generation of the CD1a+ cells and this
effect could be attributed to KLK, as ODN1a had no effect
(Figure 2A). Next we tested whether IC31H had any effect on the
activation of moDCs induced by LPS+IFNc on day 5 of culture by
Figure 4. The effect of KLK, ODN1a and IC31H on the expression of IRF family transcription factors and type I IFNs. Human moDCs
were differentiated for 5 days in the absence (control) or presence of KLK, ODN1a or IC31H added on day 0, 2 and 5 (Protocol B, Figure S2) to the
cultures or on day 5 only (Protocol C). Relative expression of IRF1, IRF3 and IRF7 as well as IFNA1, IFNA2, IFNB1 genes was measured in resting (empty
bars) and 100 ng/ml LPS +10 ng/ml IFNc-activated (black bars) DCs by QPCR. Mean6SEM values of triplicate measurements were calculated from
data of 3 independent donors.
doi:10.1371/journal.pone.0055264.g004
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using protocol B (Figure S2B). Measuring cell surface expression of
the activation molecule CD83 after 24 h we found that IC31H and
its KLK component inhibited the activation of moDCs, while
ODN1a had no effect (Figure 2B). Interestingly, the expression of
CD86, present on both resting and activated moDCs was not
modulated (data not shown). Based on these results we conclude
that IC31H modulates moDC differentiation and activation and
KLK has an essential role in these effects.
3. IC31H Modulates the Cytokine Profile of Human
Monocyte-derived Dendritic Cells
LPS and IFNc are potent stimulators of human moDCs but as it
is documented in the previous sections, IC31H has inhibitory
effects on differentiation of the CD1a+ subset and on moDC
activation monitored by CD83 expression. In line with this finding
when cells were treated with LPS+IFNc in combination with
IC31H according to protocol B, secretion of TNF-a and IL-6 was
significantly reduced (Figure 3A). Moreover, gene expression of
the chemokines CCL2, CCL7, CXCL10, and CXCL11 was also
inhibited as compared to resting moDCs (Figure 3B). Concomitant
with these effects we also found statistically significant increase in
IFNb secretion from LPS+IFNc-activated cells in the presence of
IC31H or KLK, but not ODN1a (Figure 3A). To clarify the
molecular background of these modulatory effects we sought to
investigate the activation of NF-kB- and IRF3-mediated signaling
pathways linked to chemokine, inflammatory cytokine and type I
IFN producing cells, respectively (Figure 3C). Our results show
that IC31H and KLK almost completely abolished IkBa
phosphorylation while slightly increased and extended the
phosphorylated state of IRF3, the transcription factor driving
IFNb1 gene expression. Thus IC31H is unable to activate the NF-
kB pathway but rather supports the IRF3 mediated type I IFN
response. As these signaling cascades mutually influence each
other’s functional activities, this effect could be attributed either to
the inhibition of IkBa activity or to the modulation of the balance
of IkBa and IRF3 mediated pathways upon signaling flux
redistribution [35]. These results also confirmed that this
modulatory effect is attributed to KLK, the peptide component
of IC31H.
4. Long Term Administration of IC31H Augments the
Type I IFN Response of Monocyte Derived Dendritic Cells
Considering the remarkable increase in type I IFN secretion as
a result of moDC activation in the presence of IC31H (Figure 3A)
next we tested the effects of IC31H and its components on type I
IFN pathway. In this system IC31H and its components were
added on day 0, 2 and 5 (Figure S2B) as compared to a single
treatment on day 5 (Figure S2C) combined with activation by
LPS+IFNc for 24 h and the expression profiles of selected
members of the IRF and type I IFN family genes were measured
in resting and activated moDCs by QPCR (Figure 4). IRF1 is
a known enhancer of type I IFN signaling whereas IRF3 and IRF7
Figure 5. Identification of the receptors and signaling pathways involved in the enhancement of the type I IFN response by IC31H.
Human moDCs were differentiated for 5 days in the absence (NT – ‘‘non-treated’’) or presence of KLK, ODN1a or IC31H (Protocol B, Figure S2B). In
Figures 5B, 5C, 5D and 5E moDCs were activated on day 5 by 20 mg/ml polyI:C for 24 hrs. In Figure 5F DCs were activated by 1 mg/ml CL075 and in
Figure 5G by 5 mg/ml CpG2216 (IDC: non-activated immature dendritic cells; MDC: CL075 or CpG2216-activated mature dendritic cells). A – Validation
of siRNA activity specific for TLR3 and RLR (RIG-I/MDA5) by Western blotting. B – Comparison of gene expression of type I IFN in control and RLR
siRNA treated moDCs. Mean6SEM values of triplicates performed with DCs of two independent donors are shown. C – Comparison of gene
expression of type I IFNs in control and TLR3 siRNA treated moDCs. Mean6SEM values of triplicates performed with moDCs of two independent
donors are shown. D – Comparison of the levels of secreted IFNb in control and RLR siRNA treated moDCs. Mean6SEM values of duplicates
performed with moDCs of two independent donors are shown. E – Comparison of the levels of secreted IFNb in control and TLR3 siRNA-treated
moDCs. Mean6SEM values of duplicates performed with DCs of two independent donors are shown. F – Effect of TLR7/8 activation by CL075 on
IC31H-, KLK- or ODN1a-treated moDCs monitored by IFNb ELISA. Mean6SEM values of duplicates performed with DCs of two independent donors are
shown. G – Effect of TLR9 activation by CpG2216 on IC31H-, KLK- or ODN1a-treated moDCs monitored by IFNb ELISA. Mean6SEM values of duplicates
performed with DCs of two independent donors are shown.
doi:10.1371/journal.pone.0055264.g005
Figure 6. Proposedmode of action of IC31H. A – After specific ligation of the endosomal TLRs, moDCs produce inflammatory cytokines and type
I interferons as a result of NF-kB and IRF3/7 signaling, respectively. B – When moDCs are differentiated in the presence of IC31H, they exhibit altered
cytokine profile that is characterized by suppressed production of inflammatory cytokines and significantly increased levels of IFNb.
doi:10.1371/journal.pone.0055264.g006
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are master regulators of IFNA and IFNB1 expression [36]. We
found that repeated administration of IC31H during moDC
differentiation resulted in substantial enhancement of the expres-
sion of all IRFs and type I IFN genes as compared to using IC31H
at day 5, only. These results clearly demonstrate that the
prolonged presence of IC31H increases its efficacy. Furthermore,
IRF3 gene expression was enhanced by either a single (day 5) or
repeated (day 0, 2 and 5) administration of IC31H to the similar
levels. These findings also suggest that if circulating monocytes
acting as precursors of moDCs encounter IC31H it able to
stimulate type I IFN production efficiently in developing moDCs,
but it has a less prominent effect on already differentiated moDCs.
These unique effects seem to be restricted to IC31H as it could be
induced by the combination of KLK and ODN1a but not by its
single components.
5. Mechanism of IC31H Action at the Level of Pattern
Recognition Receptors Involved in Type I IFN Responses
IFN responses can be mediated by various PRRs localized to
intracellular vesicular compartments or cytosol. To assess the
contribution of intracellular TLRs and cytosolic RIG-like
receptors (RLRs) to type I IFN production in the context of
IC31H treatment we studied the PRR ligand induced activation of
moDCs in the absence or long term presence of IC31H and its
components. To exclude the involvement of RLRs in IC31H-
modulated production of IFNb induced by polyI:C we performed
siRNA experiments in which we silenced both RIG-I and MDA5
(Figure 5A). Our results revealed that the down-regulation of
RLRs had no effect on the stimulatory effect of IC31H on the
polyI:C induced IFNb expression measured at both gene
(Figure 5B) and protein levels (Figure 5D). Similar results were
obtained for IFNa gene expression but in this case moDCs did not
produce detectable levels of IFNa (data not shown). In contrast to
these result silencing of the TLR3 gene by specific siRNA
(Figure 5A) resulted in dramatic abrogation of IFNb mRNA and
cytokine levels (Figure 5C, E). These results confirm that the type I
IFN enhancing activity of IC31H does not depend on RLR
mediated IFNb production in human moDCs (Figure 5B, D) but is
mediated by vesicular TLR3 induced signaling. This led us to
hypothesize that IC31H is able to interact with intracellular PRRs
localized to the endo/lysosomal membrane.
It is well established that cDCs express a specific combination of
TLRs that involve TLR3, TLR7, TLR8 and TLR9 however, the
functional role of TLR9 in this cell type is still controversial.
Previous studies demonstrated that in human moDCs IC31H co-
localizes with TLR9 [25] but the functional significance of this
compartmentalization has not been explored. To check the
possible booster effect of IC31H on IFNb production mediated
by the candidate vesicular sensors we used CL075 and CpG2216
as specific ligands of TLR7/8 and TLR9, respectively. Our results
showed that specific ligation of TLR7/8 by CL075 resulted in
significantly increased IFNb production, which was further
enhanced upon repeated IC31H treatment according to protocol
B (Figure 5F). Interestingly, CpG2216 stimulation of moDCs did
not induce IFNb production by itself, however, repeated pre-
treatment of moDCs by IC31H or ODN1a (protocol B) resulted in
moderate production of IFNb cytokine (Figure 5G). Thus IC31H
renders TLR9 functional in moDCs and this effect is attributed to
its ODN1a component. As TLR9 gene expression was not affected
by IC31H (data not shown) we propose that targeting IC31H or
ODN1a to LAMP1+ endolysosomal acidic membrane vesicles [25]
ensures the required pH-dependent translocation and sufficient
concentration of the CpG2216 ligand to trigger TLR9 in human
moDCs.
Discussion
Most prophylactic vaccines are based on the capability to trigger
protective antibody responses however, provoking potent cellular
immune responses against intracellular pathogens, which often
cause persistent infections, requires the priming and/or modula-
tion of inflammatory T-lymphocytes by properly activated DCs
(reviewed in [3]).
Despite their low numbers in the circulation pDCs are
considered as highly potent APCs of viral antigens and upon
activation they differentiate toward natural IFN producing cells.
This prompted us to study the effect of IC31H on this cell type.
The expression of cell surface proteins associated with the
activation and migration of pDC were not influenced by the
treatment of the cells with IC31H or its components. As the
expression of CXCR4 and CCR7 chemokines, involved in lymph
node homing of pDCs was increased only in the presence of other
blood cells but not in isolated pDCs, this phenomenon was
attributed to the indirect effect of other stimulated cells present in
peripheral blood. In line with the lack of pDC activation and
induction of chemokine and cytokine secretion these results
supported the notion that pDCs are not the primary targets of
the IC31H adjuvant. Thus we focused to analyzing the response of
human monocytes and differentiating moDC to IC31H and
monitored its effects on various PRR coupled signaling pathways.
We found that i) IC31H was efficiently accumulated in human
blood monocytes and moDCs; ii) in the presence of IC31H the
generation of inflammatory CD1a+ DCs was inhibited and the
surface expression of CD83 did not increase, but CD86 expression
remained intact; iii) the expression of chemokines and the
secretion of TNF-a and IL-6 cytokines decreased but IFNb
secretion increased; iv) long term presence of IC31H prevented or
inhibited IkBa phosphorylation while extended the phosphorylat-
ed state of IRF3; v) IC31H exhibited a booster effect on ligand
induced vesicular TLR-mediated induction of IFNb secretion.
IC31H has extensively been characterized in terms of its
adjuvant effects [20–24], intracellular localization [26] and its
role in TLR9 dependent activation of moDCs [28]. However,
understanding of its mode of action and its effects on PRR
triggered signaling cascades in human moDCs has not been
analyzed so far. To assess the short and long term in vitro effects of
IC31 on moDC activation and differentiation we set up different
treatment protocols. The experimental data revealed that IC31H
and its KLK component inhibited the transition of CD1a2 cells to
more differentiated CD1a+ moDCs and interfered with moDC
activation induced by the TLR4 ligand LPS combined with IFNc.
As a functional consequence the treated cells were unable to
exhibit the typical phenotypic and functional changes of moDC
activation, as increased expressions of CD1a and CD83, however,
CD86 expression was not affected. This semi-mature differentia-
tion and activation state of moDCs was associated to decreased
NF-kB activation and to the unusual capability of the treated cells
to secrete high amounts of IFNb under the control of and in
collaboration with IRFs. Thus IC31H could be identified as
a moDC modulator that may have a profound effect on the
balance of NF-kB and IRF3 mediated signaling pathways. This
effect was also verified by a gene array showing complete
inhibition of the mRNA expression of several CCL and CXCL
chemokine genes known to be under the control of NF-kB and
involved in the recruitment of monocytes. In our previous work we
have shown that the intracellular sensors RIG-I and MDA5 in
human moDCs are expressed in a DC subset-specific manner and
are able to trigger the IRF3 mediated IFNb pathway indepen-
dently of NF-kB activation [37] supporting the notion that their
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collaboration or independent action relies on a delicate balance
that can be harnessed for the development of potent but non
inflammatory vaccine adjuvants.
To further analyze the interplay of the type I IFN coupled
pathway with NF-kB mediated signaling we tested the involve-
ment of other IFN response-related genes and proteins. We could
demonstrate that IC31H and with lower extent KLK increase type
I IFN responses induced by the specific ligands of TLR3 or
TLR7/8. As these TLRs could be further stimulated for type I
IFN production upon receptor ligation, this modulatory effect
could be attributed in part to KLK, which facilitates the transport
and accumulation of the specific TLR ligands into endosomal
compartments, where they stimulate the resident TLRs. Although
previous results demonstrated that TLRs localized to the same
vesicular compartment may interfere with each other’s functional
activities and may exert inhibitory effects [38,39], our results point
to synergistic action of IC31H and IFN signaling. Indeed,
CpG2216 itself did not trigger type I IFN release from moDC,
whereas co-administration of the TLR9 ligand with IC31H or
ODN1 led to notable production of IFNb.
We propose that the adjuvant effects of IC31H rely on the
vesicular targeting of TLR ligands by KLK and the ODN1a-
induced triggering of TLR9 for initial type I IFN production. This
baseline effect can be further enhanced by additional TLR-specific
ligands that known to have the potential to induce vesicular
maturation essential for DC activation and potent antigen
presentation. IC31H thus acts as a signaling pathway-restricted
adjuvant. It is also important to note that the spatial distribution of
IC31H may be of high importance concerning its adjuvants effects
as long-term administration of IC31H resulted in significantly
higher expression of IRF and IFN genes as compared to a single
24 h treatment, only. We hypothesize that repeated addition of
IC31H leads to the gradual accumulation of the adjuvant in the
endosomal membranes that may contribute to this booster effect
(Figure 6).
Besides increasing the magnitude of adaptive immune re-
sponses, adjuvants also play an instructive role in driving immune
responses to the most appropriate directions to confer protection
against the target pathogen [40]. Although moDCs treated with
IC31H did not express CD1a and CD83, they kept their expression
of the costimulatory molecule CD86, which may be sufficient for
the initiation and sustainment of a proper T cell response. We
suggest, that together with the significantly increased levels of
secreted IFN-b, this may lead to a Th1-polarized immune
response. Efficient protection against intracellular pathogens
requires the activation of CD4+ helper T-cells polarized to Th1
type adaptive immune responses and stimulation of DCs to induce
potent and durable activation of CD8+ T-cells. These require-
ments can be achieved by agonists of TLR3, TLR4, TLR7/8 and
TLR9 facilitating the access of the antigen to the MHC class I
processing pathway and inducing type I IFN responses [1]. TLR
activation in the same DC presenting the antigen is a crucial
requirement of efficient CD4+ T cell activation and Th1
polarization, which also demonstrates the importance of cytokines
produced by antigen carrying APCs [41,42]. Our results clearly
show that moDCs produce increased level of IFNb when IC31H is
co-administered with endosomal TLR-ligands. This augmented
type I IFN production may potentiate and enhance the adjuvant
effect of IC31H on the adaptive immune response. Furthermore,
besides its antiviral activity, IFNb has also been shown to act as
a strong anticancer factor [43,44]. Thus, we propose that IC31H is
an effective adjuvant acting through the endosomal TLR system of
moDCs and represents a potent tool for future vaccination
strategies against intracellular pathogens and cancer.
Supporting Information
Figure S1 Characterization of the effect of IC31H and its
components on pDCs. Treatment and phenotyping of pDCs were
performed as described in Materials and Methods. pDCs were
incubated with Cy5-conjugated ODN1a, FITC-conjugated KLK
and IC31H containing both fluorescent components for 1 hr either
on ice (0uC) or at 37uC. Fluorescence intensities were measured by
flow cytometry. Unstained controls are shown as thin lines. A
typical experiment out of four is documented.
(RAR)
Figure S2 Protocols for short-term and long-term treatments of
cDCs. Figure S2A represents a system in which moDCs were
differentiated in the presence of IC31H that was added to
monocytes on day 0 and to differentiating moDC on day 2
generating 5-day resting DCs (Figure S2A). In the second system
a similar procedure was performed extended by an additional
adjuvant treatment on day 5 together with the activation of DCs
by exposure to LPS plus IFNc (LPS+ IFNc) or by various TLR
ligands to mimic inflammatory conditions (Figure S2B). According
to the third protocol, the IC31H adjuvant was added on day 5
only, combined with the activation stimuli as in protocol B (Figure
S2C).
(RAR)
Table S1 Fluorescence intensities of activated pDCs were
measured as described in Material and Methods. A – Expressions
of CD80, CD83, CD84, CD40, CD38 and CD62L on the surface
of pDCs. B – Fluorescence intensities of pDCs measured in whole-
blood and in in vitro cultured pDCs treated with IC31H, KLK and
ODN1a. Mean6SEM data of 3–4 independent experiments
performed with cells derived from independent donors are shown.
Significant changes are presented in bold (*p,0.05, **p,0.01).
(RAR)
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